The First 12 Weeks on a GLP-1, Week by Week

The first 12 weeks on a GLP-1 receptor agonist are the escalation phase. Semaglutide (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) are both started at a deliberately low dose and stepped up over the first weeks of treatment, and the shape of that ramp is written into the FDA-approved prescribing information on DailyMed. The Wegovy label, revised June 2026, describes a starting dose held for four weeks and then increased every four weeks over the first 16 weeks, and it states plainly that the schedule exists to reduce the risk of gastrointestinal adverse reactions. The Zepbound label, revised August 2026, describes a starting dose taken for four weeks that is for treatment initiation and not approved as a maintenance dosage, with increases permitted only after at least four weeks on the current dose. The two big registration trials followed the same logic: STEP 1 included 16 weeks of semaglutide dose escalation and SURMOUNT-1 included a 20-week tirzepatide dose-escalation period. So at week 12, a person following either label is still climbing, not at the destination.

That single fact explains most of what the first three months feel like. Appetite tends to change early, often within the first few doses, and then shifts again at each step. Digestive side effects cluster around the steps rather than spreading evenly across the weeks. The scale moves, but it moves under a lot of noise, and the number at week 12 says less about the eventual result than people expect. In the SURMOUNT-1 post hoc analysis by Ard and colleagues (Diabetes, Obesity and Metabolism, 2025), 82.0% of adherent tirzepatide participants had lost at least 5% of their starting weight by week 12, which means roughly one in five had not, and most of those went on to reach it later.

Everything below is organized in three four-week blocks because that is how the labels are organized, with a section on what the trials reported and one on the first follow-up. None of it is a schedule. The dose you are on, when it changes, and whether a step gets delayed are decisions your prescriber makes with you, and the label itself tells prescribers they may consider delaying an escalation when a dose is not tolerated. What this page can do is tell you what is common, what is worth writing down, and why.

The first block is the introduction dose. Both labels describe it as a starting period rather than a treatment dose, and the Zepbound label says so in as many words. Some people notice very little in week one. Others notice appetite drop within a day or two of the first injection, and a surprising number describe the change not as hunger disappearing but as fullness arriving sooner, a meal that used to be normal suddenly feeling like too much at the halfway point. Food noise, the background chatter about the next meal, is the thing people most often report going quiet, and it is also the thing they most often forget they ever had once it is gone.

Side effects in this block are usually the mildest of the 12 weeks, because the dose is the lowest, but the first one or two doses are also the first time the body has met the molecule at all. Nausea, burping, constipation and a flat, tired feeling the day after the injection are the ordinary reports. The STEP 1 publication (Wilding et al., NEJM 2021) describes nausea and diarrhea as the most common adverse events in that trial, typically transient and mild to moderate. If anything is severe, persistent, or frightening, that is a call to your prescriber or pharmacist, not a note for next month.

This is also the block where the baseline gets written, and the baseline is the entry every later one is read against. Our step-by-step on logging your first GLP-1 dose covers the four fields worth recording at the moment of the first injection. For the rest of the block, the useful habit is small: the dose date and injection site each week, one line about appetite in your own words, and a weight reading under the same conditions on as many mornings as you can manage. Do not skip the readings you dislike. A trend built only from good days is not a trend. In GLP-1 Tracker each of those lands on the same timeline, so by week four you already have a dated record of what the starting dose did rather than a vague memory of it.

Somewhere around the start of week five, if your prescriber follows the label schedule and nothing has prompted a hold, the dose steps up for the first time. Titration in general terms means exactly that: a planned increase after a period on the previous dose, repeated until the prescriber-chosen maintenance dose is reached. Our guide to how a GLP-1 dosing schedule is structured covers the logic in more depth. The amount, the timing and whether the step happens on schedule are your prescriber's decisions, and the Wegovy label explicitly tells prescribers they may consider delaying an escalation by four weeks if a dose is not tolerated. A held step is a normal part of the design, not a setback.

The first step is where side-effect timing becomes visible. The Wegovy label states that its listed adverse reactions were most frequently reported during dosage escalation. The Zepbound label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. The pooled analysis of STEP 1, 2 and 3 by Wharton and colleagues (Diabetes, Obesity and Metabolism, 2022) put figures on it for semaglutide: nausea in 43.9% of participants versus 16.1% on placebo, diarrhea in 29.7% versus 15.9%, vomiting in 24.5% versus 6.3% and constipation in 24.2% versus 11.1%, with 98.1% of gastrointestinal events mild to moderate and most occurring during or shortly after a dose escalation. For tirzepatide, the Zepbound label reports nausea in 25% to 29% of participants across doses in its pooled weight-reduction studies versus 8% on placebo. Those are trial populations on trial schedules. They tell you what is common, not what you will get.

What that means for the log is specific. A symptom in this block is more useful with two extra details attached: which week of the current dose you are in, and how many days after the injection it landed. Nausea on day two of the first week on a new dose and nausea on day six of the fourth week are different observations with the same name, and the difference is what your prescriber will ask about. Appetite often drops again at the step and then partially returns over the following weeks, which is worth a line each week so the pattern is visible later. Protein is easy to under-eat when fullness arrives early, and a rough note of whether you managed a protein source at each meal is more useful than a precise calorie count at this stage. Hydration and constipation belong in the same note, because they are usually connected.

By the third block many people are on their second stepped-up dose, appetite has usually settled into a new normal, and attention shifts to the scale. This is where expectations most often go wrong, not because the medication is not working but because a daily weight reading is a noisy instrument. Water, salt, glycogen, the contents of your gut, the time of day and where you are in a menstrual cycle all move the number by amounts that can swamp a week of real change. A reading that is up on Thursday and down on Saturday is not information about fat. It is information about Thursday.

The fix is procedural and boring, which is why it works. Weigh under fixed conditions, log every reading including the ones you would rather not, compare seven-day averages against each other rather than single days, and give the trend at least four weeks before reading anything into it. Our how-to on reading a GLP-1 weight trend lays out the method and deliberately refuses to say what rate of loss to expect, because the trials report populations and your prescriber knows your history. GLP-1 Tracker draws the smoothed trend from the readings you log, which is the practical reason to log the bad days: the line is only honest if it has all of them.

Two things are worth saying about a flat stretch in weeks nine to twelve. First, a flat week during escalation is often noise, and a flat month is the earliest point at which a plateau is even a meaningful word. Our guide to the GLP-1 weight loss plateau covers what tends to be going on when the trend genuinely stalls, and it belongs to later in the journey rather than here. Second, the SURMOUNT-1 post hoc analysis is the most useful reassurance in the literature for this exact moment: of the tirzepatide participants who had lost less than 5% by week 12, 70% had reached 5% by week 24, and their mean loss at week 72 was 11.0%. Being a slower starter in a trial did not mean being a non-responder. Whether your own trend warrants any change is a question for your prescriber, with the log in hand.

The log in this block should add non-scale observations, because they carry the weeks when the number does not: how clothes fit, energy, sleep, a photo under the same light as the first one. Nobody reconstructs those from memory.

The two trials that underpin the approved weight-management labels are the honest reference points for the first 12 weeks, provided they are read as what they are: large, controlled, adherent populations on protocol schedules with lifestyle support, followed for far longer than three months.

STEP 1 (Wilding et al., New England Journal of Medicine, 2021) randomized 1,961 adults with obesity or overweight and without diabetes to once-weekly semaglutide or placebo for 68 weeks, including 16 weeks of dose escalation. At week 68 the mean change in body weight was -14.9% with semaglutide versus -2.4% with placebo, and 86.4% of semaglutide participants versus 31.5% of placebo participants had lost at least 5%. Nausea and diarrhea were the most common adverse events, typically transient and mild to moderate, and 4.5% of semaglutide participants versus 0.8% on placebo discontinued because of gastrointestinal events. Week 12 in STEP 1 sat three quarters of the way through escalation, so the week-12 experience in that trial was an experience of a still-rising dose.

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) randomized 2,539 adults with obesity or overweight and without diabetes to once-weekly tirzepatide at three maintenance doses or placebo for 72 weeks, including a 20-week dose-escalation period. Mean weight change at week 72 ranged from -15.0% at the lowest maintenance dose to -20.9% at the highest, versus -3.1% with placebo, and 85% to 91% of tirzepatide participants lost at least 5% compared with 35% on placebo. Gastrointestinal events were the most common adverse events, mostly mild to moderate and mostly during escalation. The 2025 post hoc analysis by Ard and colleagues is the only week-12 figure in either program that this page will quote: 82.0% of adherent tirzepatide participants were early responders with at least 5% loss at week 12, and the remainder averaged 11.0% loss by the end of the trial.

Your number may differ for reasons that have nothing to do with effort. Trial participants met inclusion criteria, followed a fixed escalation schedule, received structured lifestyle counselling, and are reported as averages that flatten a wide spread of individual curves. A step delayed for tolerability, a different medication or a compounded product all change the picture. The right comparison at week 12 is not your weight against a trial average. It is your own trend against your own baseline, read by the person who prescribed the medication.

Most people have at least one prescriber contact inside the first 12 weeks, often timed around a titration step, and the exact timing is set by your prescriber rather than by any general rule. Whether it is a full appointment, a portal message or a pharmacist conversation, it is short, and the value of three months of logging is that it turns "how is it going?" into a set of answers.

The questions a first follow-up tends to circle are predictable. Did you take every dose, and on which days? Where did the injections go? What happened to appetite, and did it change at the step? Which side effects showed up, how bad were they, how long after each injection did they land, and did they ease as the weeks on a dose went by? What has the weight trend done, read as an average rather than a single reading? What are you managing to eat, and in particular is protein holding up? Every one of those is a thing you logged, or did not, in the preceding eleven weeks.

The skill at the appointment is condensing rather than handing over the lot. Three or four lines the night before: what changed since the start, the side-effect pattern with its timing relative to the dose, what you have already tried for it, and the two questions you actually want answered. Keep the detailed record in your pocket for the moments when the prescriber wants to see a specific week. GLP-1 Tracker holds the dose dates, sites, side effects, notes, weight trend and meal logs together on the iPhone, so the detailed record is a scroll rather than a reconstruction, and none of it goes to our servers.

Then the boundary, stated plainly because it matters more at week 12 than at any other point. Whether the next step happens on schedule, is delayed, or the dose is held where it is, is a prescribing decision. So is anything to do with a missed or late dose, which differs between products and is covered in each product's own prescribing information and Instructions for Use. This page describes what is common in the first 12 weeks on a GLP-1 and what is worth writing down. It does not, and cannot, tell you what to do with a dose. Bring the notes; leave the decisions to your prescriber and pharmacist.